Compare UHS & BMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UHS | BMRN |
|---|---|---|
| Founded | 1978 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hospital/Nursing Management | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.4B | 10.0B |
| IPO Year | 1994 | 1999 |
| Metric | UHS | BMRN |
|---|---|---|
| Price | $184.43 | $54.29 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 12 | 18 |
| Target Price | ★ $230.25 | $88.22 |
| AVG Volume (30 Days) | 760.3K | ★ 1.8M |
| Earning Date | 04-27-2026 | 04-30-2026 |
| Dividend Yield | ★ 0.43% | N/A |
| EPS Growth | ★ 37.34 | N/A |
| EPS | ★ 23.10 | 1.80 |
| Revenue | ★ $17,364,829,000.00 | $1,313,646,000.00 |
| Revenue This Year | $7.70 | $14.30 |
| Revenue Next Year | $4.96 | $11.65 |
| P/E Ratio | ★ $8.02 | $30.90 |
| Revenue Growth | 9.71 | ★ 17.62 |
| 52 Week Low | $152.33 | $50.76 |
| 52 Week High | $246.33 | $71.28 |
| Indicator | UHS | BMRN |
|---|---|---|
| Relative Strength Index (RSI) | 32.06 | 35.41 |
| Support Level | $181.18 | $54.35 |
| Resistance Level | $189.57 | $56.21 |
| Average True Range (ATR) | 5.34 | 1.65 |
| MACD | 0.04 | -0.38 |
| Stochastic Oscillator | 14.29 | 11.67 |
Universal Health Services primarily offers healthcare services through its behavioral health centers, acute care hospitals, and related outpatient facilities. As of late 2025, the company operated 346 inpatient behavioral health centers, 29 acute care hospitals, and many supportive outpatient facilities. Its operations are concentrated in the US, particularly in Nevada (21% of 2025 operating profits), Texas (19%), and California (13%), although it does have some exposure to the UK behavioral health market (6% of 2025 sales) too. While its acute care services account for over 55% of revenue, the behavioral health centers sport higher margins and account for over 55% of pretax profits.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.